| Compound Information | SONAR Target prediction |
| Name: | Promazine hydrochloride |
| Unique Identifier: | LOPAC 01148 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | C17ClH21N2S |
| Molecular Weight: | 299.714 g/mol |
| X log p: | 17.925 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 31.78 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 2 |
| Rotatable Bond Count: | 4 |
| Canonical Smiles: | Cl.CN(C)CCCN1c2ccccc2Sc2ccccc12 |
| Class: | Dopamine |
| Action: | Antagonist |
| Selectivity: | DRD2 |
| Generic_name: | Trimeprazine |
| Chemical_iupac_name: | N,N,2-trimethyl-3-phenothiazin-10-yl-propan-1-amine |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA451781 |
| Kegg_compound_id: | C07172 |
| Drugbank_id: | APRD00258 |
| Melting_point: | 68 oC |
| H2o_solubility: | 0.942 mg/L |
| Logp: | 5.162 |
| Isoelectric_point: | 9.05 |
| Cas_registry_number: | 84-96-8 |
| Mass_spectrum: | http://webbook.nist.gov/cgi/cbook.cgi?Spec=C84968&Index=0&Type=Mass&Large=on |
| Drug_category: | Antipruritics; Phenothiazine Derivatives; ATC:D04AA10; ATC:R06AD02; ATC:R06AD05 |
| Indication: | Used to prevent and relieve allergic conditions which cause pruritus (itching) and urticaria (some allergic skin reactions). |
| Pharmacology: | Trimeprazine (also known as Alimemazine) is a tricyclic antihistamine, similar in structure to the phenothiazine antipsychotics, but differing in the ring-substitution and chain characteristics. Trimeprazine is in the same class of drugs as chlorpromazine (Thorazine) and trifluoperazine (Stelazine); however, unlike the other drugs in this class, trimeprazine is not used clinically as an anti-psychotic. It acts as an anti-histamine, a sedative, and an anti-emetic (anti-nausea). Trimeprazine is used principally as an anti-emetic, to prevent motion sickness or as an anti-histamine in combination with other medications in cough and cold preparations. Tricyclic antihistamines are also structurally-related to the tricyclic antidepressants, explaining the antihistaminergic adverse effects of these two drug classes and also the poor tolerability profile of tricyclic H1-antihistamines. |
| Mechanism_of_action: | Trimeprazine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. |
| Organisms_affected: | Humans and other mammals |
| Found: 24 nonactive as graph: single | with analogs | [1] << Back 1 2 3 4 5 6 7 8 9 10 Next >> [24] |
| Species: | 4932 |
| Condition: | DEP1 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.6510±0.0579828 |
| Normalized OD Score: sc h | 0.9669±0.0305172 |
| Z-Score: | -1.3870±1.31472 |
| p-Value: | 0.333986 |
| Z-Factor: | -5.5532 |
| Fitness Defect: | 1.0967 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 12 | << Back 1 2 |
| 212560 | N,N,2,2-tetramethyl-3-phenothiazin-10-yl-propan-1-amine hydrochloride |
| 450886 | N,N-dimethyl-3-phenothiazin-10-yl-propan-1-amine |
| 657285 | N,N-dimethyl-3-phenothiazin-10-yl-propan-1-amine; hydrogen(+1) cation; chloride |
| 5259899 | dimethyl-(3-phenothiazin-10-ylpropyl)azanium |
| 5458371 | (2,2-dimethyl-3-phenothiazin-10-yl-propyl)-dimethyl-azanium chloride |
| 6604496 | (2S)-N,N,2-trimethyl-3-phenothiazin-10-yl-propan-1-amine |
| internal high similarity DBLink | Rows returned: 1 |
| SPE01500509 | 1.0000 |
| active | Cluster 17541 | Additional Members: 13 | Rows returned: 4 |
| SPE01503934 | 0.32258064516129 |
| SPE01500184 | 0 |
| LAT005D03 | 0 |
| LOPAC 00253 | 0 |
Service provided by the
Mike Tyers Laboratory